2. Academic Validation
  3. Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma

Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma

  • ACS Chem Biol. 2014 May 16;9(5):1086-91. doi: 10.1021/cb4008524.
Hong Wu 1,  Wenchao Wang,  Feiyang Liu,  Ellen L Weisberg,  Bei Tian,  Yongfei Chen,  Binhua Li,  Aoli Wang,  Beilei Wang,  Zheng Zhao,  Douglas W McMillin,  Chen Hu,  Hong Li,  Jinhua Wang,  Yanke Liang,  Sara J Buhrlage,  Junting Liang,  Jing Liu,  Guang Yang,  Jennifer R Brown,  Steven P Treon,  Constantine S Mitsiades,  James D Griffin,  Qingsong Liu,  Nathanael S Gray
Affiliations

Affiliation

  • 1 High Magnetic Field laboratory, Chinese Academy of Sciences , Mailbox 1110, 350 Shushanhu Road, Hefei 230031, Anhui, P. R. China.
PMID: 24556163 DOI: 10.1021/cb4008524
Abstract

Btk is a member of the TEC family of non-receptor tyrosine kinases whose deregulation has been implicated in a variety of B-cell-related diseases. We have used structure-based drug design in conjunction with kinome profiling and cellular assays to develop a potent, selective, and irreversible Btk kinase inhibitor, QL47, which covalently modifies Cys481. QL47 inhibits Btk kinase activity with an IC50 of 7 nM, inhibits autophosphorylation of Btk on Tyr223 in cells with an EC50 of 475 nM, and inhibits phosphorylation of a downstream effector PLCγ2 (Tyr759) with an EC50 of 318 nM. In Ramos cells QL47 induces a G1 cell cycle arrest that is associated with pronounced degradation of Btk protein. QL47 inhibits the proliferation of B-cell lymphoma Cancer cell lines at submicromolar concentrations.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z